216 related articles for article (PubMed ID: 24276455)
21. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Ping SY; Wu CL; Yu DS
Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Wu CL; Ping SY; Yu CP; Yu DS
Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
[TBL] [Abstract][Full Text] [Related]
24. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
25. Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.
Tomoda C; Moatamed F; Naeim F; Hershman JM; Sugawara M
Exp Biol Med (Maywood); 2008 Nov; 233(11):1433-40. PubMed ID: 18791128
[TBL] [Abstract][Full Text] [Related]
26. Response to sunitinib in medullary thyroid cancer.
Kelleher FC; McDermott R
Ann Intern Med; 2008 Apr; 148(7):567. PubMed ID: 18378960
[No Abstract] [Full Text] [Related]
27. Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.
Abdel-Aziz AK; Shouman S; El-Demerdash E; Elgendy M; Abdel-Naim AB
Chem Biol Interact; 2014 Jun; 217():28-40. PubMed ID: 24751611
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
29. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
Di Desidero T; Fioravanti A; Orlandi P; Canu B; Giannini R; Borrelli N; Man S; Xu P; Fontanini G; Basolo F; Kerbel RS; Francia G; Danesi R; Bocci G
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1465-73. PubMed ID: 23969186
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib for the treatment of thyroid cancer.
Gómez-Sáez JM
Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
[TBL] [Abstract][Full Text] [Related]
31. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
33. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
34. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
Drosten M; Stiewe T; Pützer BM
Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
[TBL] [Abstract][Full Text] [Related]
35. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.
Koga K; Hattori Y; Komori M; Narishima R; Yamasaki M; Hakoshima M; Fukui T; Maitani Y
Cancer Sci; 2010 Apr; 101(4):941-7. PubMed ID: 20704575
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer.
Yoon YK; Im SA; Min A; Kim HP; Hur HS; Lee KH; Han SW; Song SH; Youn Oh D; Kim TY; Kim WH; Bang YJ
Cancer Lett; 2012 Aug; 321(2):128-36. PubMed ID: 22266184
[TBL] [Abstract][Full Text] [Related]
37. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells.
Grosse J; Warnke E; Wehland M; Pietsch J; Pohl F; Wise P; Magnusson NE; Eilles C; Grimm D
Apoptosis; 2014 Mar; 19(3):480-90. PubMed ID: 24213562
[TBL] [Abstract][Full Text] [Related]
39. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
40. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]